Lenzing Biocel Paskov

Biocel's employees rose 3.56% yoy to 407 in 2019

By Helgi Analytics - December 4, 2020

Lenzing Biocel Paskov employed 407 employees in 2019, up 3.56% compared to the previous year. Historically, between 200...

Biocel's net profit fell 21.6% yoy to CZK 1,111 mil in 2019

By Helgi Analytics - December 4, 2020

Lenzing Biocel Paskov made a net profit of CZK 1,111 mil in 2019, down 21.6% compared to the previous year. Total sales reached CZK ...

Biocel's Cash & Cash Equivalents rose 38.8% yoy to CZK 1,585 mil in 2019

By Helgi Analytics - December 4, 2020

Lenzing Biocel Paskov's total assets reached CZK 7,358 mil at the end of 2019, down 0.049% compared to the previous year. ...

Profit Statement 2017 2018 2019
Sales CZK mil 5,568 5,249 5,285
Gross Profit CZK mil 2,105 1,710 2,015
EBITDA CZK mil 2,327 2,083 1,938
EBIT CZK mil 1,909 1,662 1,530
Financing Cost CZK mil 14.4 0 0
Pre-Tax Profit CZK mil 1,957 1,672 1,405
Net Profit CZK mil 1,621 1,417 1,111
Dividends CZK mil 1,770 1,100 ...
Balance Sheet 2017 2018 2019
Total Assets CZK mil 8,216 7,362 7,358
Non-Current Assets CZK mil 4,246 4,070 3,994
Current Assets CZK mil 3,969 3,291 33,612
Working Capital CZK mil 1,513 1,760 1,347
Shareholders' Equity CZK mil 6,711 6,249 6,303
Liabilities CZK mil 1,505 1,113 1,056
Total Debt CZK mil 409 0 0
Net Debt CZK mil -1,706 -1,143 -1,587
Ratios 2017 2018 2019
ROE % 26.8 21.9 17.7
ROCE % 28.2 24.5 19.9
Gross Margin % 37.8 32.6 38.1
EBITDA Margin % 41.8 39.7 36.7
EBIT Margin % 34.3 31.7 29.0
Net Margin % 29.1 27.0 21.0
Net Debt/EBITDA -0.733 -0.549 -0.819
Net Debt/Equity % -25.4 -18.3 -25.2
Cost of Financing % 2.31 0 ...
Cash Flow 2017 2018 2019
Total Cash From Operations CZK mil 2,394 1,452 1,802
Total Cash From Investing CZK mil -341 -245 -259
Total Cash From Financing CZK mil -894 -2,179 1,100
Net Change In Cash CZK mil 1,159 -971 2,643
Cash Conversion Cycle days 129 150 122
Cash Earnings CZK mil 2,039 1,839 1,519
Free Cash Flow CZK mil 2,052 1,207 1,543

Get all company financials in excel:

Download Sample   $19.99

overview Unit 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
income statement                            
Sales CZK mil ...             4,330 5,259 5,618 5,126 5,568    
Gross Profit CZK mil ...             583 1,167 1,778 1,591 2,105    
EBIT CZK mil ...             163 940 1,511 1,375 1,909    
Net Profit CZK mil ...             -39.1 575 996 1,297 1,621    
                               
ROE % ...             -1.51 20.7 28.1 27.3 26.8    
EBIT Margin % ...             3.76 17.9 26.9 26.8 34.3    
Net Margin % ...             -0.904 10.9 17.7 25.3 29.1    
Employees               398 384 369 368 380    
balance sheet                            
Total Assets CZK mil ...             6,500 6,846 7,082 7,067 8,216    
Non-Current Assets CZK mil ...             5,113 4,876 4,541 4,343 4,246    
Current Assets CZK mil ...             1,386 1,969 2,539 2,722 3,969    
                               
Shareholders' Equity CZK mil ...             2,597 2,962 4,130 5,364 6,711    
Liabilities CZK mil ...             3,903 3,884 2,952 1,703 1,505    
Non-Current Liabilities CZK mil ...             200 560 144 618 330    
Current Liabilities CZK mil ...             2,010 1,972 1,868 983 834    
                               
Net Debt/EBITDA ...             5.40 1.65 0.268 -0.065 -0.733    
Net Debt/Equity % ...             105 78.8 12.8 -2.21 -25.4    
Cost of Financing % ... ... ... ... ... ... ... ... 2.83 9.61 2.57 2.31   ...
cash flow                            
Total Cash From Operations CZK mil ... ...           -449 -99.8 834 1,730 2,394    
Total Cash From Investing CZK mil ... ...           -634 714 798 -245 -341    
Total Cash From Financing CZK mil ... ...           969 -254 -1,297 -1,296 -894    
Net Change In Cash CZK mil ... ...           -113 360 336 188 1,159    
income statement Unit 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
income statement                            
Sales CZK mil ...             4,330 5,259 5,618 5,126 5,568    
Cost of Goods & Services CZK mil ...             3,747 4,092 3,839 3,535 3,463    
Gross Profit CZK mil ...             583 1,167 1,778 1,591 2,105    
Staff Cost CZK mil ...             231 238 258 259 287    
Other Operating Cost (Income) CZK mil ...             -155 -488 -455 -499 -509    
EBITDA CZK mil ...             507 1,417 1,975 1,831 2,327    
Depreciation CZK mil ...             344 477 464 456 418    
EBIT CZK mil ...             163 940 1,511 1,375 1,909    
Net Financing Cost CZK mil ...             209 228 596 23.1 47.9    
Financing Cost CZK mil ... ... ... ... ... ... ... ... 78.9 195 27.4 14.4    
Extraordinary Cost CZK mil ...             0 0 0 0 -95.9    
Pre-Tax Profit CZK mil ...             -46.0 712 915 1,352 1,957    
Tax CZK mil ...             -6.89 137 -81.0 55.1 106    
Minorities CZK mil ...             0 0 ... ... ... ... ...
Net Profit CZK mil ...             -39.1 575 996 1,297 1,621    
Net Profit Avail. to Common CZK mil ...             -39.1 575 996 1,297 1,621    
Dividends CZK mil ... ... ... ... ... ... ... ... ... 0 460 1,770   ...
growth rates                            
Total Revenue Growth % ... ...           14.6 21.5 6.82 -8.76 8.63    
Staff Cost Growth % ... ...           -29.8 2.91 8.37 0.517 10.6    
EBITDA Growth % ... ...           117 180 39.4 -7.31 27.1    
EBIT Growth % ... ...           -637 477 60.7 -9.00 38.8    
Pre-Tax Profit Growth % ... ...           -63.3 -1,648 28.5 47.8 44.8    
Net Profit Growth % ... ...           -60.5 -1,570 73.1 30.2 25.0    
ratios                            
ROE % ...             -1.51 20.7 28.1 27.3 26.8    
ROA % ...             -0.649 8.62 14.3 18.3 21.2    
ROCE % ... ...           -0.777 10.2 17.0 22.2 28.2    
Gross Margin % ...             13.5 22.2 31.7 31.0 37.8    
EBITDA Margin % ...             11.7 27.0 35.2 35.7 41.8    
EBIT Margin % ...             3.76 17.9 26.9 26.8 34.3    
Net Margin % ...             -0.904 10.9 17.7 25.3 29.1    
Payout Ratio % ... ... ... ... ... ... ... ... ... 0 35.5 109   ...
Cost of Financing % ... ... ... ... ... ... ... ... 2.83 9.61 2.57 2.31   ...
Net Debt/EBITDA ...             5.40 1.65 0.268 -0.065 -0.733    
balance sheet Unit 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
balance sheet                            
Cash & Cash Equivalents CZK mil ...             70.5 431 766 955 2,113    
Receivables CZK mil ...             428 457 777 762 777    
Inventories CZK mil ...             649 928 996 1,005 1,078    
Other ST Assets CZK mil ...             240 154 0.384 0 0    
Current Assets CZK mil ...             1,386 1,969 2,539 2,722 3,969    
Property, Plant & Equipment CZK mil ...             5,099 4,866 4,535 4,338 4,242    
LT Investments & Receivables CZK mil ...             1.40 1.40 1.40 1.40 1.40    
Intangible Assets CZK mil ...             12.4 8.16 5.15 3.43 3.33    
Goodwill CZK mil ...             0 0 0 0 0    
Non-Current Assets CZK mil ...             5,113 4,876 4,541 4,343 4,246    
Total Assets CZK mil ...             6,500 6,846 7,082 7,067 8,216    
                               
Trade Payables CZK mil ...             677 476 394 367 342    
Short-Term Debt CZK mil ...             1,445 1,270 1,297 405 409    
Other ST Liabilities CZK mil ...             -112 226 177 211 83.2    
Current Liabilities CZK mil ...             2,010 1,972 1,868 983 834    
Long-Term Debt CZK mil ...             1,366 1,497 0 432 0    
Other LT Liabilities CZK mil ...             -1,165 -937 144 185 330    
Non-Current Liabilities CZK mil ...             200 560 144 618 330    
Liabilities CZK mil ...             3,903 3,884 2,952 1,703 1,505    
Equity Before Minority Interest CZK mil ...             2,597 2,962 4,130 5,364 6,711    
Minority Interest CZK mil ...             0 0 0 0 0    
Equity CZK mil ...             2,597 2,962 4,130 5,364 6,711    
growth rates                            
Total Asset Growth % ... ...           16.8 5.32 3.45 -0.210 16.3    
Shareholders' Equity Growth % ... ...           0.775 14.1 39.4 29.9 25.1    
Net Debt Growth % ... ...           59.6 -14.8 -77.3 -122 1,338    
Total Debt Growth % ... ...           47.9 -1.57 -53.1 -35.4 -51.2   ...
ratios                            
Total Debt CZK mil ...             2,811 2,767 1,297 838 409    
Net Debt CZK mil ...             2,739 2,335 529 -119 -1,706    
Working Capital CZK mil ...             399 909 1,379 1,400 1,513    
Capital Employed CZK mil ...             5,512 5,785 5,920 5,743 5,759    
Net Debt/Equity % ...             105 78.8 12.8 -2.21 -25.4    
Current Ratio ...             0.690 0.999 1.36 2.77 4.76    
Quick Ratio ...             0.248 0.450 0.826 1.75 3.47    
cash flow Unit 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
cash flow                            
Net Profit CZK mil ...             -39.1 575 996 1,297 1,621    
Depreciation CZK mil ...             344 477 464 456 418    
Non-Cash Items CZK mil ... ...           -786 -642 -156 -1.63 467    
Change in Working Capital CZK mil ... ...           32.6 -510 -470 -21.3 -113    
Total Cash From Operations CZK mil ... ...           -449 -99.8 834 1,730 2,394    
                               
Capital Expenditures CZK mil ... ...           -634 714 798 -245 -344    
Other Investing Activities CZK mil ... ...           0 0 0 0.132 2.22    
Total Cash From Investing CZK mil ... ...           -634 714 798 -245 -341    
                               
Dividends Paid CZK mil ... ...           59.1 -210 172 0 -460    
Issuance Of Shares CZK mil ... ...           0 0 1.00 0 0    
Issuance Of Debt CZK mil ... ...           910 -44.1 -1,470 -460 -429    
Other Financing Activities CZK mil ... ...           634 -714 -797 -591 337    
Total Cash From Financing CZK mil ... ...           969 -254 -1,297 -1,296 -894    
Net Change In Cash CZK mil ... ...           -113 360 336 188 1,159    
ratios                            
Days Sales Outstanding days ...             36.1 31.7 50.5 54.3 50.9    
Days Sales Of Inventory days ...             63.2 82.7 94.7 104 114    
Days Payable Outstanding days ...             66.0 42.4 37.4 37.9 36.1    
Cash Conversion Cycle days ...             33.3 72.0 108 120 129    
Cash Earnings CZK mil ...             305 1,052 1,460 1,753 2,039    
Free Cash Flow CZK mil ... ...           -1,082 614 1,632 1,484 2,052    
Capital Expenditures (As % of Sales) % ... ...           14.6 -13.6 -14.2 4.79 6.17    
other ratios Unit 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
                             
Employees               398 384 369 368 380    
Cost Per Employee USD per month ...             2,474 2,416 2,440 2,326 2,678    
Cost Per Employee (Local Currency) CZK per month ...             48,408 51,635 58,231 58,691 62,840    
Material & Energy (As % of Sales) % ... ... ... ... ... ... ... ... 60.2 51.9 52.7 47.0    
Services (As % of Sales) % ... ... ... ... ... ... ... ... 17.6 16.4 16.3 15.1    
Staff Cost (As % of Sales) % ...             5.34 4.52 4.59 5.06 5.15    
Effective Tax Rate % ...             15.0 19.2 -8.85 4.08 5.41    
Total Revenue Growth (5-year average) % ... ... ... ... ... ...   4.43 11.0 6.53 5.54 8.07    
Total Revenue Growth (10-year average) % ... ... ... ... ... ... ... ... ... ... ... 2.70    

Get all company financials in excel:

Download Sample   $19.99

Biocel's Net Margin fell 22.2% yoy to 21.0% in 2019

By Helgi Analytics - December 4, 2020

Lenzing Biocel Paskov made a net profit of CZK 1,111 mil with revenues of CZK 5,285 mil in 2019, down by 21.6% and up by 0.683%, respectively, compared to the previous year. This translates into a net margin of 21.0%. Historically, between 2007 and 2019...

Biocel's ROCE fell 18.7% yoy to 19.9% in 2019

By Helgi Analytics - December 4, 2020

Lenzing Biocel Paskov made a net profit of CZK 1,111 mil in 2019, down 21.6% compared to the previous year. Historically, between 2007 and 2019, the company's net profit reached a high of CZK 1,621 mil in 2017 and a low of CZK -99.0 mil in 2012. The resul...

Biocel's Net Debt/EBITDA fell 49.2% yoy to -0.819 in 2019

By Helgi Analytics - December 4, 2020

Lenzing Biocel Paskov's net debt stood at CZK -1,587 mil and accounted for -25.2% of equity at the end of 2019. The ratio is down 6.88 pp compared to the previous year. Historically, the firm’s net debt to equity reached a high of 105% in 2013 and ...

Biocel's Capital Expenditures fell 6.11% yoy to CZK 260 mil in 2019

By Helgi Analytics - December 4, 2020

Lenzing Biocel Paskov invested a total of CZK 260 mil in 2019, up 6.11% compared to the previous year. Historically, between 2008 - 2019, the company's investments stood at a high of CZK 958 mil in 2012 and a low of CZK -798 mil in 2015. ...

More News

Biocel Paskov a.s. is a Czech Republic-based manufacturer of viscose pulp for the textile industry in Austria, the Netherlands, Estonia, and internationally. The Company was founded in 2001 and is based in Paskov, Czech Republic. Biocel Paskov a.s. operates as a subsidiary of Lenzing Aktiengesellschaft.

Lenzing Biocel Paskov Logo

Finance

Lenzing Biocel Paskov has been growing its sales by 0.097% a year on average in the last 5 years. EBITDA has grown on average by 6.46% a year during that time to total of CZK 1,938 mil in 2019, or 36.7% of sales. That’s compared to 37.8% average margin seen in last five years.

The company netted CZK 1,111 mil in 2019 implying ROE of 17.7% and ROCE of 19.9%. Again, the average figures were 24.4% and 22.4%, respectively when looking at the previous 5 years.

Lenzing Biocel Paskov’s net debt amounted to CZK -1,587 mil at the end of 2019, or -25.2% of equity. When compared to EBITDA, net debt was -0.819x, down when compared to average of -0.380x seen in the last 5 years.